{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:19:44Z","timestamp":1792030784426,"version":"4.4.0"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":2133,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This document provides clinical recommendations for the pharmacologic treatment of chronic obstructive pulmonary disease (COPD). It represents a collaborative effort on the part of a panel of expert COPD clinicians and researchers along with a team of methodologists under the guidance of the American Thoracic Society.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Comprehensive evidence syntheses were performed on all relevant studies that addressed the clinical questions and critical patient-centered outcomes agreed upon by the panel of experts. The evidence was appraised, rated, and graded, and recommendations were formulated using the Grading of Recommendations, Assessment, Development, and Evaluation approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After weighing the quality of evidence and balancing the desirable and undesirable effects, the guideline panel made the following recommendations: 1) a strong recommendation for the use of long-acting \u03b22-agonist (LABA)\/long-acting muscarinic antagonist (LAMA) combination therapy over LABA or LAMA monotherapy in patients with COPD and dyspnea or exercise intolerance; 2) a conditional recommendation for the use of triple therapy with inhaled corticosteroids (ICS)\/LABA\/LAMA over dual therapy with LABA\/LAMA in patients with COPD and dyspnea or exercise intolerance who have experienced one or more exacerbations in the past year; 3) a conditional recommendation for ICS withdrawal for patients with COPD receiving triple therapy (ICS\/LABA\/LAMA) if the patient has had no exacerbations in the past year; 4) no recommendation for or against ICS as an additive therapy to long-acting bronchodilators in patients with COPD and blood eosinophilia, except for those patients with a history of one or more exacerbations in the past year requiring antibiotics or oral steroids or hospitalization, for whom ICS is conditionally recommended as an additive therapy; 5) a conditional recommendation against the use of maintenance oral corticosteroids in patients with COPD and a history of severe and frequent exacerbations; and 6) a conditional recommendation for opioid-based therapy in patients with COPD who experience advanced refractory dyspnea despite otherwise optimal therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The task force made recommendations regarding the pharmacologic treatment of COPD based on currently available evidence. Additional research in populations that are underrepresented in clinical trials is needed, including studies in patients with COPD 80 years of age and older, those with multiple chronic health conditions, and those with a codiagnosis of COPD and asthma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.202003-0625st","type":"journal-article","created":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T20:36:16Z","timestamp":1586810176000},"page":"e56-e69","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":294,"title":["Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline"],"prefix":"10.1093","volume":"201","author":[{"given":"Linda","family":"Nici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0343-3234","authenticated-orcid":false,"given":"Manoj J.","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Charbek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3221-8875","authenticated-orcid":false,"given":"Paul E.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia M.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard J.","family":"Criner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5538-4190","authenticated-orcid":false,"given":"Gavin C.","family":"Donaldson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dreher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent S.","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0246-594X","authenticated-orcid":false,"given":"Andrea S.","family":"Gershon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MeiLan K.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry A.","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando J.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula M.","family":"Meek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1243-8571","authenticated-orcid":false,"given":"Michael I.","family":"Polkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo A.","family":"Puhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0419-7862","authenticated-orcid":false,"given":"Mohsen","family":"Sadatsafavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don D.","family":"Sin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George R.","family":"Washko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadwiga A.","family":"Wedzicha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4762-3542","authenticated-orcid":false,"given":"Shawn D.","family":"Aaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,1]]},"reference":[{"key":"2026030321435856400_bib1","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease","year":"2019"},{"key":"2026030321435856400_bib2","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","article-title":"GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation\u2019s direction and strength","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"2026030321435856400_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jclinepi.2018.09.007","article-title":"Evidence to decision framework provides a structured \u201croadmap\u201d for making GRADE guidelines recommendations","volume":"104","author":"Li","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"2026030321435856400_bib4","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med Care"},{"key":"2026030321435856400_bib5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1378\/chest.13-1579","article-title":"Once-daily umeclidinium\/vilanterol 125\/25 mcg in COPD: a randomized, controlled study","volume":"145","author":"Celli","year":"2014","journal-title":"Chest"},{"key":"2026030321435856400_bib6","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.rmed.2008.12.014","article-title":"Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD","volume":"103","author":"Tashkin","year":"2009","journal-title":"Respir Med"},{"key":"2026030321435856400_bib7","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1164\/rccm.201505-1048OC","article-title":"FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol\/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease","volume":"192","author":"Mahler","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321435856400_bib8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/1753465814559209","article-title":"Effects of a combination of umeclidinium\/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials","volume":"8","author":"Maltais","year":"2014","journal-title":"Ther Adv Respir Dis"},{"key":"2026030321435856400_bib9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.rmed.2017.02.008","article-title":"A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium\/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease","volume":"125","author":"D\u2019Urzo","year":"2017","journal-title":"Respir Med"},{"key":"2026030321435856400_bib10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1471-2466-14-178","article-title":"Efficacy and safety of aclidinium bromide\/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study","volume":"14","author":"Singh","year":"2014","journal-title":"BMC Pulm Med"},{"key":"2026030321435856400_bib11","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.chest.2016.11.028","article-title":"Efficacy and safety of glycopyrrolate\/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD","volume":"151","author":"Martinez","year":"2017","journal-title":"Chest"},{"key":"2026030321435856400_bib12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.rmed.2017.03.015","article-title":"Long-term safety and efficacy of glycopyrrolate\/formoterol metered dose inhaler using novel Co-Suspension\u2122 Delivery Technology in patients with chronic obstructive pulmonary disease","volume":"126","author":"Hanania","year":"2017","journal-title":"Respir Med"},{"key":"2026030321435856400_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.rmed.2016.05.007","article-title":"Long-term safety of aclidinium bromide\/formoterol fumarate fixed-dose combination: results of a randomized 1-year trial in patients with COPD","volume":"116","author":"Donohue","year":"2016","journal-title":"Respir Med"},{"key":"2026030321435856400_bib14","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.rmed.2014.10.002","article-title":"Efficacy and safety of umeclidinium\/vilanterol 62.5\/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial","volume":"108","author":"Maleki-Yazdi","year":"2014","journal-title":"Respir Med"},{"key":"2026030321435856400_bib15","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.rmed.2015.08.002","article-title":"Tiotropium + olodaterol shows clinically meaningful improvements in quality of life","volume":"109","author":"Singh","year":"2015","journal-title":"Respir Med"},{"key":"2026030321435856400_bib16","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1183\/09031936.00136014","article-title":"Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)","volume":"45","author":"Buhl","year":"2015","journal-title":"Eur Respir J"},{"key":"2026030321435856400_bib17","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1183\/09031936.00200212","article-title":"Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study","volume":"42","author":"Bateman","year":"2013","journal-title":"Eur Respir J"},{"key":"2026030321435856400_bib18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","article-title":"Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study","volume":"1","author":"Wedzicha","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2026030321435856400_bib19","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-146-8-200704170-00152","article-title":"Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial","volume":"146","author":"Aaron","year":"2007","journal-title":"Ann Intern Med"},{"key":"2026030321435856400_bib20","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2147\/COPD.S119032","article-title":"Umeclidinium\/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study","volume":"12","author":"Kerwin","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026030321435856400_bib21","first-page":"716","article-title":"Long-term maintenance bronchodilation with indacaterol\/glycopyrrolate versus indacaterol in moderate-to-severe COPD patients: the FLIGHT 3 study","volume":"3","author":"Ferguson","year":"2016","journal-title":"Chronic Obstr Pulm Dis (Miami)"},{"key":"2026030321435856400_bib22","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.rmed.2013.06.001","article-title":"Efficacy and safety of once-daily umeclidinium\/vilanterol 62.5\/25 mcg in COPD","volume":"107","author":"Donohue","year":"2013","journal-title":"Respir Med"},{"key":"2026030321435856400_bib23","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.rmed.2008.07.020","article-title":"Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study","volume":"102","author":"Vogelmeier","year":"2008","journal-title":"Respir Med"},{"key":"2026030321435856400_bib24","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2147\/COPD.S72482","article-title":"Efficacy and safety of combining olodaterol Respimat(\u00ae) and tiotropium HandiHaler(\u00ae) in patients with COPD: results of two randomized, double-blind, active-controlled studies","volume":"9","author":"ZuWallack","year":"2014","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026030321435856400_bib25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/COPD.S51592","article-title":"Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study","volume":"9","author":"Vincken","year":"2014","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026030321435856400_bib26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2213-2600(18)30102-4","article-title":"Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial","volume":"6","author":"Calverley","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026030321435856400_bib27","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S2213-2600(14)70065-7","article-title":"Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials","volume":"2","author":"Decramer","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2026030321435856400_bib28","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1136\/thoraxjnl-2011-201140","article-title":"Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison","volume":"67","author":"Mahler","year":"2012","journal-title":"Thorax"},{"key":"2026030321435856400_bib29","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","article-title":"Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"2026030321435856400_bib30","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med"},{"key":"2026030321435856400_bib31","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","article-title":"Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial","volume":"6","author":"Ferguson","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026030321435856400_bib32","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(16)00100-4","article-title":"Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial","volume":"4","author":"Watz","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2026030321435856400_bib33","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","article-title":"Withdrawal of inhaled glucocorticoids and exacerbations of COPD","volume":"371","author":"Magnussen","year":"2014","journal-title":"N Engl J Med"},{"key":"2026030321435856400_bib34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1164\/rccm.201803-0405OC","article-title":"Long-Term triple therapy de-escalation to indacaterol\/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial","volume":"198","author":"Chapman","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321435856400_bib35","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(15)00106-X","article-title":"Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials","volume":"3","author":"Pascoe","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2026030321435856400_bib36","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S2213-2600(19)30190-0","article-title":"Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial","volume":"7","author":"Pascoe","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026030321435856400_bib37","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/thoraxjnl-2015-207021","article-title":"Blood eosinophils and inhaled corticosteroid\/long-acting \u03b2-2 agonist efficacy in COPD","volume":"71","author":"Pavord","year":"2016","journal-title":"Thorax"},{"key":"2026030321435856400_bib38","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1164\/rccm.201701-0193OC","article-title":"Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment: data from the FLAME trial","volume":"195","author":"Roche","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321435856400_bib39","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1164\/rccm.201502-0235LE","article-title":"Blood eosinophils: a biomarker of response to extrafine beclomethasone\/formoterol in chronic obstructive pulmonary disease","volume":"192","author":"Siddiqui","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321435856400_bib40","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(17)30188-5","article-title":"Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial","volume":"389","author":"Vestbo","year":"2017","journal-title":"Lancet"},{"key":"2026030321435856400_bib41","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S2213-2600(19)30195-X","article-title":"Blood eosinophils as a continuous variable in the treatment of COPD: impact on the guidelines","volume":"7","author":"van den Berge","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026030321435856400_bib42","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJM199906243402502","article-title":"Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease","volume":"340","author":"Niewoehner","year":"1999","journal-title":"N Engl J Med"},{"key":"2026030321435856400_bib43","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/qjmed\/92.7.395","article-title":"Oral corticosteroid trials in the management of stable chronic obstructive pulmonary disease","volume":"92","author":"Davies","year":"1999","journal-title":"QJM"},{"key":"2026030321435856400_bib44","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1378\/chest.109.5.1156","article-title":"Effects of long-term treatment with corticosteroids in COPD","volume":"109","author":"Renkema","year":"1996","journal-title":"Chest"},{"key":"2026030321435856400_bib45","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/thx.48.4.309","article-title":"Effects of high dose inhaled beclomethasone dipropionate, 750 micrograms and 1500 micrograms twice daily, and 40 mg per day oral prednisolone on lung function, symptoms, and bronchial hyperresponsiveness in patients with non-asthmatic chronic airflow obstruction","volume":"48","author":"Weir","year":"1993","journal-title":"Thorax"},{"key":"2026030321435856400_bib46","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1164\/ajrccm\/139.1.126","article-title":"Effects of oral morphine on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease","volume":"139","author":"Light","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"2026030321435856400_bib47","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/bmj.327.7414.523","article-title":"Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea","volume":"327","author":"Abernethy","year":"2003","journal-title":"BMJ"},{"key":"2026030321435856400_bib48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1378\/chest.104.1.175","article-title":"Effects of nebulized morphine sulfate on the exercise tolerance of the ventilatory limited COPD patient","volume":"104","author":"Beauford","year":"1993","journal-title":"Chest"},{"key":"2026030321435856400_bib49","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1183\/09031936.93.04080926","article-title":"Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the \u201cpink puffer\u201d syndrome","volume":"4","author":"Eiser","year":"1991","journal-title":"Eur Respir J"},{"key":"2026030321435856400_bib50","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1183\/09031936.97.10102270","article-title":"Lack of effect of high doses of inhaled morphine on exercise endurance in chronic obstructive pulmonary disease","volume":"10","author":"Jankelson","year":"1997","journal-title":"Eur Respir J"},{"key":"2026030321435856400_bib51","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/thx.51.6.596","article-title":"Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease","volume":"51","author":"Leung","year":"1996","journal-title":"Thorax"},{"key":"2026030321435856400_bib52","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1378\/chest.109.4.975","article-title":"Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD","volume":"109","author":"Light","year":"1996","journal-title":"Chest"},{"key":"2026030321435856400_bib53","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1164\/ajrccm.157.6.9711061","article-title":"The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease","volume":"157","author":"Poole","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321435856400_bib54","doi-asserted-by":"crossref","first-page":"610921","DOI":"10.1155\/2012\/610921","article-title":"Effect of nebulized morphine on dyspnea of mustard gas-exposed patients: a double-blind randomized clinical trial study","volume":"2012","author":"Shohrati","year":"2012","journal-title":"Pulm Med"},{"key":"2026030321435856400_bib55","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/thx.44.5.387","article-title":"Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease","volume":"44","author":"Young","year":"1989","journal-title":"Thorax"},{"key":"2026030321435856400_bib56","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jpainsymman.2011.05.007","article-title":"Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease","volume":"43","author":"Jensen","year":"2012","journal-title":"J Pain Symptom Manage"},{"key":"2026030321435856400_bib57","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1183\/09031936.97.10051079","article-title":"Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine","volume":"10","author":"Noseda","year":"1997","journal-title":"Eur Respir J"},{"key":"2026030321435856400_bib58","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1056\/NEJM198112313052703","article-title":"Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases","volume":"305","author":"Woodcock","year":"1981","journal-title":"N Engl J Med"},{"key":"2026030321435856400_bib59","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/bmj.286.6366.675","article-title":"Dihydrocodeine for breathlessness in \u201cpink puffers\u201d","volume":"286","author":"Johnson","year":"1983","journal-title":"Br Med J (Clin Res Ed)"}],"updated-by":[{"DOI":"10.1164\/rccm.v202erratum5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T00:00:00Z","timestamp":1600128000000}}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/201\/9\/e56\/67180933\/ajrccm_201_9_e56.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/201\/9\/e56\/67180933\/ajrccm_201_9_e56.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T02:44:10Z","timestamp":1772592250000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/201\/9\/e56\/8496645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":59,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,5,1]]},"published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202003-0625st","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2020,5,1]]},"assertion":[{"value":"2020-05-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}